Reducing ribosomal gene transcription may protect tissues by limiting genome damage
With mitochondrial clearance suppressed, reducing ribosomal gene transcription could protect aging tissues by limiting genome-damaging hybrids of ribonucleic acid and deoxyribonucleic acid. Continued functional and survival benefits after genome damage is restored would reject this mechanism.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Enzyme
mTOR
A protein whose suppression reduces excessive transcription of ribosomal genes in the proposed pathway
Where this hypothesis actsIn ageing cells, including when mitophagy is suppressed
Hypotheses on this target 4
Inhibition4
Activation
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation
What is proposed
Inhibition
Suppress mTOR activity
With whatSmall molecule
HowTreatment with rapamycin
Possible result
Possible reduction in new genomic damage, preservation of tissue function and reduced malignant transformation
From the recordПри подавлении mTOR уменьшается чрезмерная транскрипция рибосомных генов.
Extracellular nucleic acid
RNA–DNA hybrids
Structures formed by RNA and DNA that can obstruct transcription and contribute to genomic damage
Where this hypothesis actsPathological hybrids in ribosomal genes in ageing cells
Hypotheses on this target 1
Silencing
Clearance restoration1
Neutralisation
Accelerated excretion
What is proposed
Clearance restoration
Reduce the formation or persistence of pathological RNA–DNA hybrids
With whatProtein or peptide as the agent
HowSuppress mTOR or remove hybrids using ribonuclease H1 with verified nuclear localization and controls for mitochondrial effects
Possible result
Possible reduction in new ribosomal gene breaks and reproduction of the protective effect of mTOR suppression
From the recordНаправленное удаление патологических гибридов рибонуклеазой H1 воспроизводит защиту и уменьшает дополнительный эффект рапамицина в диапазоне, свободном от потолочного эффекта.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Several aging tissues might benefit from preventing the same kind of damage inside their cells. The unexpected move is to locate that shared protection at ribosomal genes, the DNA instructions for making the RNA components of cells’ protein-building machinery. This pipeline-generated proposal predicts that suppressing mTOR protects those sites without requiring mitophagy, the removal of mitochondria, the cell structures involved in energy production; it is not a measured result.
- Suppressing mTOR is proposed to reduce excessive copying of ribosomal genes into RNA.
- Reduced copying is proposed to decrease persistent RNA–DNA hybrids at those genes.
- Fewer persistent hybrids are proposed to reduce interference with copying and the formation of new DNA damage.
- Less new DNA damage is proposed to preserve function in several aging tissues and reduce the chance that cells become cancerous.
- This shared protection is proposed to operate without mitophagy and without reducing how strongly damage in one organ worsens damage in another.
Several workshops could suffer fewer breakdowns if their instruction-copying machines stopped leaving sheets stuck inside them. The workshops would improve even if the trouble they caused one another stayed the same.
Where the picture breaks: RNA–DNA hybrids are molecular structures, not loose paper. The picture does not establish that slowing copying removes them, or that preventing damage at these genes protects several tissues.
- Master questionstep 01 of 04
Aging processes may worsen one another, so acting on a shared cause could benefit several body systems at once.
Rests on: The goal seeks life-extending interventions that act on a common cause of damage across systems.
AssumptionThe motivating premise assumes that a shared causal target can be altered to produce benefits across several systems. The supplied material does not establish that premise.
- Goal pillarstep 02 of 04
The intended output is a set of life-extension ideas that work through distinct causes.
Rests on: The master question explicitly requests ideas for interventions acting on shared causes of aging.
Stated in the chain - Gap questionstep 03 of 04
Life extension from suppressing mTOR might survive the removal of mitophagy even if damage continues to spread between systems unchanged and only one cause of death is delayed.
Rests on: The goal requires a distinction between protecting several systems and extending life by postponing a single fatal condition.
LeapThe preceding stages do not explain the selection of mTOR suppression or supply the proposed causal connection to mitophagy. These enter here as the specific case to investigate, not as established consequences of the goal.
- Hypothesisstep 04 of 04
Suppressing mTOR is proposed to reduce excessive transcription, the copying of DNA instructions into RNA, at ribosomal genes. Fewer persistent RNA–DNA hybrids would then mean less new damage to the genome, the cell’s genetic material, preserving several tissues and reducing the chance that cells become cancerous without requiring mitophagy.S5S6
Rests on: The gap motivates an explanation that does not require mitophagy. The Plant Cell (2017, S5) reports that controlling RNA–DNA hybrids helped reduce DNA damage at ribosomal genes in Arabidopsis plant chloroplasts, the structures that perform photosynthesis; eLife (2016, S6) links such hybrids at ribosomal genes to disrupted copying processes in yeast. These sources support a local hybrid–damage connection, not protection from mTOR suppression in aging tissues.
Supported by literature
What is carried, and what is not. Two screened sources, S5 and S6, support the local connection between RNA–DNA hybrids and damage or disrupted copying at ribosomal genes, but neither establishes the proposed sequence in aging tissues. The supplied Cell Reports abstract (2026, S8) also reports that loss of a protein helping transcription proceed in yeast reduced transcription while increasing hybrids and damage, so less transcription cannot itself be treated as evidence of protection; that experiment did not test mTOR suppression.S5S6S8
Where the reasoning is carried by something unstated · 2
- Master question. The motivating premise assumes that a shared causal target can be altered to produce benefits across several systems. The supplied material does not establish that premise.
- Gap question. The preceding stages do not explain the selection of mTOR suppression or supply the proposed causal connection to mitophagy. These enter here as the specific case to investigate, not as established consequences of the goal. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Protection after adding ribonuclease H1, an enzyme that removes RNA from RNA–DNA hybrids, could arise from effects on mitochondria rather than removal of hybrids at the proposed DNA sites. What closes it: The supplied design requires verified placement in the nucleus, the compartment containing the targeted genes, a control enzyme unable to perform the cutting reaction, and independent measurements of mitochondrial condition. Effects at the targeted ribosomal genes must also be verified.
- Little additional benefit from rapamycin, the drug used here to suppress mTOR, after hybrid removal could reflect a maximum measurable benefit rather than a shared protective route. What closes it: The supplied prediction requires a range in which further improvement remains possible. Hybrid abundance and new DNA damage must be measured alongside function so that overlapping benefits are connected to the proposed cause.
- Longer survival could be credited to protection across tissues when it actually reflects delayed death from one tumor or improved breathing, as the rival explanations allow. What closes it: The test must distinguish causes of death and measure function in several tissues alongside hybrid abundance and new DNA damage. Its decisive reversal requires verified restoration of the targeted hybrids and damage while mTOR remains suppressed; survival alone does not separate the explanations.
What would make this wrong. The supplied proposal explicitly rejects this explanation if treatment preserves functional and lifespan benefits after the relevant DNA damage has been experimentally restored. That observation is decisive only if restoration at the intended sites is verified while mTOR remains suppressed; an unsuccessful attempt to restore damage would not break the chain.
What it would change. If the predicted causal reversals held, damage formation at ribosomal genes would become a candidate shared cause through which one intervention could protect several aging tissues. The search for a broadly protective intervention would then need to distinguish reducing damage within each tissue from weakening damage transmission between organs, because this proposal requires only the former. Even a positive result in the old mice described by a rival explanation would not establish human life extension or protection across all tissues and causes of death.
Sources read · 9
PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway. · Oncotarget · 2016
“Our data show that PICT-1 triggers pro-death autophagy through inhibition of rRNA transcription and the inactivation of AKT/mTOR/p70S6K pathway, independent of nucleolar disruption and p53 activation.”
Does not settle: This cancer-cell study does not establish that mTOR suppression reduces rDNA transcription, RNA-DNA hybrids, genome damage, aging-cell damage formation, tissue function, cancer risk, or the necessity of mitophagy for the proposed pathway.
“Thus, the lifespan-extension observed in the afo1 Δ strain occurs in the presence of ERCs and is not further increased when ERCs are absent, consequently ERCs do not influence longevity in the afo1Δ strain.”
Does not settle: Источник описывает репликативное старение дрожжей при делеции AFO1. Он не устанавливает влияние подавления mTOR на транскрипцию рибосомных генов, гибриды РНК-ДНК, новые повреждения генома, митофагию, функцию тканей или злокачественное преобразование.
The bridge-like lipid transfer protein Vps13 are required for NVJ integrity and nucleophagy. · Biochemical and biophysical research communications · 2025
“Vps13 accumulates at the NVJ upon inactivation of the target of rapamycin complex 1 (TORC1), a process necessary for NVJ integrity.”
Does not settle: Источник не рассматривает транскрипцию рибосомных генов, гибриды РНК-ДНК, повреждения генома, стареющие клетки, ткани, злокачественное преобразование или необходимость митофагии. Работа выполнена на почкующихся дрожжах в условиях дефицита питательных веществ.
RNase H1 Cooperates with DNA Gyrases to Restrict R-Loops and Maintain Genome Integrity in Arabidopsis Chloroplasts. · The Plant cell · 2017
“The interaction between AtRNH1C and AtGyrases was critical for R-loop homeostasis in chloroplast and important to release the transcription-replication conflicts in the highly transcribed and replication originated cp-rDNA regions and thus to reduce the DNA damage.”
Does not settle: Источник описывает хлоропласты Arabidopsis. Он не устанавливает роль подавления mTOR, стареющих клеток, сохранения функции тканей, риска злокачественного преобразования, митофагии или межорганных коэффициентов усиления.
RNase H enables efficient repair of R-loop induced DNA damage. · eLife · 2016
“R-loops found at the rDNA are associated with increased rates of recombination ( , ), RNA polymerase pileups ( ), and stalled replication forks ( ).”
Does not settle: This yeast study does not test mTOR inhibition, reduced ribosomal-gene transcription, aging cells or tissues, cancer risk, mitophagy, or interorgan effects.
Molecular basis of CX-5461-induced DNA damage response in primary vascular smooth muscle cells. · Heliyon · 2024
“Our results indicate that in vascular SMCs, increased formation of G-quadruplex or R-loop structures is unlikely to have a major contribution to CX-5461-induced DDR.”
Does not settle: This study examines CX-5461 in primary vascular smooth muscle cells, not mTOR suppression or aging tissues. It does not establish that reducing ribosomal gene transcription prevents new genome damage, preserves multiple tissue functions, reduces malignant transformation, or that mitophagy is unnecessary for such a pathway.
Paf1 Counteracts transcriptional arrest to maintain rDNA stability during pol I elongation. · Cell reports · 2026
“Loss of Paf1, an elongation factor associated with RNA polymerase, reduces rDNA transcription, stability, and lifespan. In paf1 mutants, R-loops accumulate within the rDNA, generating single-stranded regions prone to breakage. This triggers double-strand breaks at replication forks, leading to rDNA copy number variation and DNA fragmentation.”
Does not settle: Исследование выполнено на почкующихся дрожжах и не рассматривает подавление mTOR, стареющие клетки, ткани, митофагию, межорганные эффекты или риск злокачественного преобразования. Абстракт не устанавливает, как изменение транскрипции рибосомных генов влияет на повреждение генома при подавлении mTOR.
Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK. · Signal transduction and targeted therapy · 2026
“Compared with their wild-type littermates, aged HPS-KO mice presented reduced LKB1 and AMPK activation and elevated mechanistic target of rapamycin kinase (mTOR) activity in both quiescent and regenerating livers.”
Does not settle: Источник не исследует подавление mTOR, транскрипцию рибосомных генов, гибриды РНК-ДНК, повреждения генома, роль митофагии или межорганные эффекты.
Editorial: Insights in aging, metabolism and redox biology: 2024. · Frontiers in aging · 2025
“Roark and Iffland provide a comprehensive review of rapamycin’s emerging role as a potential off-label therapeutic for age-related diseases, including Alzheimer’s disease, as well as its proposed use in slowing the aging process.”
Does not settle: Источник не устанавливает влияние подавления mTOR на транскрипцию рибосомных генов, РНК-ДНК-гибриды, повреждения генома, функцию тканей, злокачественное преобразование или необходимость митофагии.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does blocking a growth-control protein still extend mouse life when damaged cell powerhouses cannot be cleared?
Original wording · exactly as the pipeline generated it
Сохранится ли продление жизни при подавлении mTOR после выключения предполагаемого посредника, митофагии, если межсистемное усиление повреждений останется прежним, а весь выигрыш объяснит отсрочка одной причины смерти?
What this question is asking
The question asks whether removing damaged energy-producing structures inside cells is necessary for a treatment to extend mouse life. It concerns suppression of mammalian target of rapamycin (mTOR), a protein involved in controlling cell growth, after disabling mitophagy, the process that removes those structures. The relevant comparison is whether suppression still increases remaining lifespan relative to no suppression when this removal process is disabled, compared with when it remains available. The question also considers a conditional explanation: damage in different body systems might continue to worsen other systems' damage, while the entire survival benefit comes from postponing just one cause of death.
- Mammalian target of rapamycin (mTOR)
- A protein involved in controlling cell growth. Suppression means reducing its activity; the question asks whether the resulting lifespan effect requires removal of damaged cellular powerhouses.
- Mitochondria
- Structures inside cells involved in producing usable energy, described here as cellular powerhouses. Their removal is the proposed link between treatment and longer life.
- Mitophagy
- The cellular process that removes mitochondria, including damaged ones. The question treats it as a possible necessary step in the lifespan effect, which the supplied sources do not establish.
- Autophagy
- The broader cellular process for removing and recycling material within cells. Mitophagy is the mitochondria-focused form; a finding about the broader process does not automatically establish the particular role of mitophagy.
- Mediator and mediation
- A mediator is an intermediate process through which an intervention causes an outcome. Here, mediation would mean that suppression of mTOR extends life through its effect on mitophagy, rather than the two simply being associated.
- Intersystem damage amplification
- The proposed process in which damage in one body system worsens damage in another. Its persistence during treatment is a condition considered by the question, not a finding established by the supplied sources.
- Rapamycin
- The treatment evaluated in the mouse lifespan findings quoted in S2. Those findings describe survival responses but do not establish the proposed role of mitophagy.
- Corylin
- The compound studied in S3. The supplied quotation reports a lifespan benefit in female mice without a comparable benefit in males.
- Median lifespan
- The time by which half of a studied group has died. It summarizes survival and does not identify which causes of death changed.
- Survival rate at a stated age
- The proportion of a group still alive at that age. S3 reports a comparison at 125 weeks; the supplied quotation does not give the underlying proportions.
- Mouse strain
- A mouse breeding line with a particular inherited background. S2 reports that strain influences the size of the lifespan response.
- Kisspeptin-10
- The molecule used in S5 to stimulate cellular removal processes. The supplied quotation describes a route independent of mTOR, so it does not establish mediation of a treatment that suppresses mTOR.
- Cellular signaling
- Processes through which activity in one part of a cell changes activity elsewhere in it. A signaling connection alone does not establish an effect on whole-animal lifespan.
- Human neuronal cell line
- Human cells maintained in laboratory culture and used to study nerve-cell processes. Findings in these cells do not by themselves establish survival effects in an animal.
- Hippocampus and cultured hippocampal tissue
- The hippocampus is a brain region. Cultured hippocampal tissue is tissue from that region maintained outside the animal; S5 includes this preparation alongside cell cultures and aging rats.
mTOR suppression is associated with longer mouse survival, mitophagy is its proposed cellular mediator, and the survival gain might occur with unchanged intersystem damage amplification because only one cause of death is delayed.
The proposed explanation places removal of damaged cellular powerhouses between blocking a growth-control protein and longer life. It contrasts protection across several body systems with a scenario in which damage still spreads between systems but one fatal condition occurs later. Establishing these links would distinguish a shared protective process from a narrower explanation of longer survival.
S2 reports generally favorable mouse lifespan findings for rapamycin, and S3 reports longer life in female mice receiving corylin. Neither supplied quotation establishes that removal of damaged cellular structures mediates those benefits. S5 instead reports stimulation of that removal through a route independent of mTOR; it does not establish the proposed mediation. None of the supplied sources establishes unchanged damage amplification between systems or a survival gain fully explained by delaying one cause of death. Those last conditions are hypothetical in the question, and this background-focused selection is too limited to establish or refute the complete premise.S2S3S5
The same question asked without the part nothing read establishes:
- Does suppressing the growth-control protein extend mouse life when removal of damaged cellular powerhouses is disabled?
- Does longer mouse life under suppression of the growth-control protein reflect lasting benefits across several body systems or postponement of one cause of death?
- The lifespan benefit persists Under the question's assumption that removal of damaged cellular powerhouses has been disabled, a persisting benefit would mean that this removal is not necessary for the entire survival effect. If postponement of one cause of death accounts for all of that benefit, longer life would not by itself demonstrate protection across several body systems.
- The lifespan benefit disappears Losing the benefit would be consistent with the removal process being necessary for the survival effect in the stated conditions. That result alone would still not establish that the process protects several systems or interrupts damage spreading between them.
- The lifespan benefit becomes smaller A smaller benefit would be consistent with the removal process contributing to, but not fully accounting for, longer survival. The remaining benefit would still need to be distinguished from the question's alternative explanation of postponing one cause of death.
The proposed explanation links suppression of the growth-control protein to removal of damaged cellular structures, then to lasting benefits across several body systems, and finally to longer life. Each connection matters because longer survival alone does not establish the preceding steps. Under the question's alternative explanation, postponing one fatal disease could extend life while damage elsewhere continues. Mistaking that outcome for protection across several systems would overstate what the survival findings establish.
Подавление mTOR уровня RL-2 связано с мышиной выживаемостью; митофагическое посредничество уровня RL-1 показано на клетках.
Выигрыш оставшейся жизни должен сопровождаться устойчивой пользой нескольким системам и проверенным общим посредничеством за единый горизонт наблюдения.
Не установлено, объясняет ли митофагия многосистемный выигрыш жизни; подавление отдельной смертельной патологии может воспроизводить наблюдаемую выживаемость.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
При подавлении mTOR уменьшается чрезмерная транскрипция рибосомных генов. Это сокращает образование устойчивых гибридов РНК и ДНК, препятствующих работе транскрипционного аппарата и способствующих повреждению генома. В уже стареющих клетках снижается образование новых геномных повреждений, что сохраняет функцию нескольких тканей и уменьшает вероятность злокачественного преобразования. Митофагия для этого пути необязательна. Общее звено представляет собой образование повреждений в рибосомных генах; межорганные коэффициенты усиления могут сохраняться.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При подавленной митофагии лечение уменьшает гибриды РНК и ДНК и новые разрывы в рибосомных генах до появления функциональной пользы. Направленное удаление патологических гибридов рибонуклеазой H1 воспроизводит защиту и уменьшает дополнительный эффект рапамицина в диапазоне, свободном от потолочного эффекта. Избирательное восстановление исходного уровня гибридов при сохранённом подавлении mTOR отменяет защиту. Если лечение сохраняет функциональную и жизненную пользу при экспериментально восстановленном геномном повреждении, эта версия отвергается.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable reductions, temporal ordering, intervention effects, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Картирование гибридов и повреждений генома доступно. Избирательное изменение гибридов в рибосомных генах сложнее: широкая экспрессия рибонуклеазы H1 может затронуть митохондрии. Нужны проверенная ядерная локализация, контроль каталитически неактивного фермента и независимое измерение митохондриального состояния.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При подавленной митофагии лечение уменьшает гибриды РНК и ДНК и новые разрывы в рибосомных генах до появления функциональной пользы. Направленное удаление патологических гибридов рибонуклеазой H1 воспроизводит защиту и уменьшает дополнительный эффект рапамицина в диапазоне, свободном от потолочного эффекта. Избирательное восстановление исходного уровня гибридов при сохранённом подавлении mTOR отменяет защиту. Если лечение сохраняет функциональную и жизненную пользу при экспериментально восстановленном геномном повреждении, эта версия отвергается.
- What would separate them
Rapamycin may extend life by changing calcium control of breathing-muscle contraction predicts: При подтверждённой блокаде митофагии рапамицин сохраняет выигрыш оставшейся жизни и повышает устойчивость диафрагмы к повторным сокращениям. Сопоставимое подавление mTOR генетическим способом этого результата не воспроизводит. Лиганд FKBP12, сохраняющий необходимое кальциевое действие и не подавляющий mTOR, воспроизводит оба эффекта. Избирательное устранение кальциевого действия рапамицина отменяет выигрыш при сохранённом подавлении mTOR. Сохранение пользы генетического подавления mTOR после такого устранения опровергает гипотезу.
- What would separate them
Growth-signal inhibition may release a brake on protein kinase B and limit cell death predicts: После блокады митофагии сохраняются краткий ответ AKT, уменьшение апоптоза после повторной нагрузки и замедление функционального ухудшения нескольких систем. Избирательное устранение вызванного лечением ответа AKT отменяет эти эффекты при сопоставимом подавлении mTOR. Модель, построенная по ответам на одиночные слабые нагрузки, заранее предсказывает меньший пик повреждения при их сочетании. Если защита сохраняется при устранённом ответе AKT либо измеренный ответ усиливает повреждение, гипотеза отвергается.
- Rival 03 of 04What would separate them
Lysosomal acidity may mimic faster mitochondrial removal predicts: Изменение сигнала mt-Keima объясняется независимо измеренной кислотностью и количеством ранее накопленного репортёра. После соответствующей калибровки увеличение потока исчезает; независимое отслеживание доставки и разрушения меченых митохондрий также не выявляет ускорения. При этом подавление mTOR замедляет рост опухоли даже после устранения дополнительных механизмов остальных гипотез. Длительные траектории заранее выбранных неопухолевых функций остаются прежними. Подтверждение ускоренного удаления целых митохондрий независимыми методами опровергает оптическую часть гипотезы.
- Rival 04 of 04What would separate them
Ubiquitin-dependent protein disposal may preserve tissue function despite defective mitophagy predicts: После выключения митофагии сохраняются ускоренное разрушение заранее меченых повреждённых цитозольных белков и функциональная польза. Устранение именно вызванного лечением прироста убиквитин-зависимого разрушения отменяет пользу, хотя подавление mTOR и изменения транскрипции рибосомных генов сохраняются. Независимое восстановление протеасомного потока возвращает защиту. Сохранение пользы при отсутствии дополнительного разрушения соответствующих белков опровергает гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.